Literature DB >> 26277091

The Effect of Bleeding Risk and Frailty Status on Anticoagulation Patterns in Octogenarians With Atrial Fibrillation: The FRAIL-AF Study.

Marie-Claude D Lefebvre1, Maude St-Onge1, Maude Glazer-Cavanagh1, Laurence Bell1, John Nam Kha Nguyen1, Patrick Viet-Quoc Nguyen2, Cara Tannenbaum3.   

Abstract

BACKGROUND: Older adults are at increased risk of atrial fibrillation (AF), its thromboembolic complications, and bleeding. A significant percentage of octogenarians do not receive anticoagulation therapy. The objective of this study was to investigate the effect of thromboembolic risk, bleeding risk, and frailty on the anticoagulation status of octogenarians hospitalized with AF.
METHODS: A cross-sectional study was conducted in 682 hospitalized patients aged 80 years and older with AF or atrial flutter in Montreal, Québec. Consumption of warfarin or a new oral anticoagulant was documented. Medical record data were used to determine each patient's frailty status using the Clinical Frailty Scale (CFS) and to evaluate the risk of stroke (CHADS2 [Congestive Heart Failure, Hypertension, Age, Diabetes, Stroke/Transient Ischemic Attack]) and bleeding (HAS-BLED [Hypertension, Abnormal renal/liver function, Stroke, Bleeding history or predisposition, Labile international normalized ratio, Elderly (> 65 years) Drugs/alcohol concomitantly]). Univariable and multivariable logistic regression analyses were used to examine the effect of frailty status and the risk of stroke and bleeding on the probability of receiving anticoagulation therapy.
RESULTS: Seventy percent of octogenarians with AF received anticoagulation therapy (n = 475). A high risk of stroke (CHADS2 = 3 compared with CHADS2 = 1, odds ratio [OR], 3.58; 95% confidence interval [CI], 1.09-11.77), and the absence of severe frailty (CFS < 7; OR, 3.41; 95% CI, 1.84-6.33) were independently associated with anticoagulant use in multivariable analyses. A high risk of bleeding (HAS-BLED score ≥ 3; OR, 0.33; 95% CI, 0.12-0.86) was associated with the absence of anticoagulation.
CONCLUSIONS: Our study suggests a higher prevalence of appropriate anticoagulation among octogenarians with AF than reported in previous studies. Further work is needed to develop and disseminate tools to optimize the use of anticoagulants in this high-risk population.
Copyright © 2016 Canadian Cardiovascular Society. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26277091     DOI: 10.1016/j.cjca.2015.05.012

Source DB:  PubMed          Journal:  Can J Cardiol        ISSN: 0828-282X            Impact factor:   5.223


  34 in total

1.  Adherence to antithrombotic therapy guidelines improves mortality among elderly patients with atrial fibrillation: insights from the REPOSI study.

Authors:  Marco Proietti; Alessandro Nobili; Valeria Raparelli; Laura Napoleone; Pier Mannuccio Mannucci; Gregory Y H Lip
Journal:  Clin Res Cardiol       Date:  2016-05-31       Impact factor: 5.460

2.  Influence of frailty on anticoagulant prescription and clinical outcomes after 1-year follow-up in hospitalised older patients with atrial fibrillation.

Authors:  Alejandra Gullón; Francesc Formiga; Jesús Díez-Manglano; José María Mostaza; José María Cepeda; Antonio Pose; Jesús Castiella; Carmen Suárez-Fernández
Journal:  Intern Emerg Med       Date:  2018-09-06       Impact factor: 3.397

3.  Geriatric Elements and Oral Anticoagulant Prescribing in Older Atrial Fibrillation Patients: SAGE-AF.

Authors:  Jane S Saczynski; Saket R Sanghai; Catarina I Kiefe; Darleen Lessard; Francesca Marino; Molly E Waring; David Parish; Robert Helm; Felix Sogade; Robert Goldberg; Jerry Gurwitz; Weijia Wang; Tanya Mailhot; Benita Bamgbade; Bruce Barton; David D McManus
Journal:  J Am Geriatr Soc       Date:  2019-10-01       Impact factor: 5.562

Review 4.  Appropriateness of Oral Anticoagulants for the Long-Term Treatment of Atrial Fibrillation in Older People: Results of an Evidence-Based Review and International Consensus Validation Process (OAC-FORTA 2016).

Authors:  Martin Wehling; Ronan Collins; Victor M Gil; Olivier Hanon; Roland Hardt; Martin Hoffmeister; Pedro Monteiro; Terence J Quinn; Dieter Ropers; Giuseppe Sergi; Freek W A Verheugt
Journal:  Drugs Aging       Date:  2017-07       Impact factor: 3.923

Review 5.  Prevention and Treatment of Acute Stroke in the Nonagenarians and Beyond: Medical and Ethical Issues.

Authors:  Tiberiu A Pana; Jesus A Perdomo-Lampignano; Phyo K Myint
Journal:  Curr Treat Options Neurol       Date:  2019-05-08       Impact factor: 3.598

Review 6.  Arrhythmias in Patients ≥80 Years of Age: Pathophysiology, Management, and Outcomes.

Authors:  Anne B Curtis; Roshan Karki; Alexander Hattoum; Umesh C Sharma
Journal:  J Am Coll Cardiol       Date:  2018-05-08       Impact factor: 24.094

7.  Relationship between frailty, polypharmacy, and underprescription in older adults living in nursing homes.

Authors:  Marta Gutiérrez-Valencia; Mikel Izquierdo; Esther Lacalle-Fabo; Itxaso Marín-Epelde; María Fernanda Ramón-Espinoza; Thamara Domene-Domene; Álvaro Casas-Herrero; Arkaitz Galbete; Nicolás Martínez-Velilla
Journal:  Eur J Clin Pharmacol       Date:  2018-03-27       Impact factor: 2.953

8.  Frailty Status Affects the Decision for Long-Term Anticoagulation Therapy in Elderly Patients with Atrial Fibrillation.

Authors:  Panteleimon E Papakonstantinou; Natalia I Asimakopoulou; John A Papadakis; Dimitrios Leventis; Michail Panousieris; George Mentzantonakis; Ermis Hoda; Simeon Panagiotakis; Achilleas Gikas
Journal:  Drugs Aging       Date:  2018-10       Impact factor: 3.923

Review 9.  What is the Impact of Frailty on Prescription of Anticoagulation in Elderly Patients with Atrial Fibrillation? A Systematic Review and Meta-Analysis.

Authors:  Zardasht Oqab; Payam Pournazari; Robert S Sheldon
Journal:  J Atr Fibrillation       Date:  2018-04-30

10.  Geriatric Syndromes and Atrial Fibrillation: Prevalence and Association with Anticoagulant Use in a National Cohort of Older Americans.

Authors:  Sachin J Shah; Margaret C Fang; Sun Y Jeon; Steven E Gregorich; Kenneth E Covinsky
Journal:  J Am Geriatr Soc       Date:  2020-09-28       Impact factor: 5.562

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.